Role of brain cytochrome P450 (CYP2D) in the metabolism of monoaminergic neurotransmitters

Pharmacological Reports

Volumn 65, Issue 6, 2013, Pages 1519-1528

  Haduch, Anna ^a   Bromek, Ewa ^a   Daniel, Wladyslawa A ^a  

^a INSTITUTE OF PHARMACOLOGY   (Poland)

Author keywords

Antidepressants; Brain; Cytochrome P450; Dopamine; Neuroleptics; Serotonin

Indexed keywords

ANTIDEPRESSANT AGENT; CYTOCHROME P450 2D; CYTOCHROME P450 2D6; DOPAMINE; ISOENZYME; MELATONIN; NEUROLEPTIC AGENT; NEUROTRANSMITTER; PSYCHOTROPIC AGENT; SEROTONIN; TYRAMINE;

CATALYSIS; DOPAMINE BRAIN LEVEL; DRUG MECHANISM; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME KINETICS; ENZYME LOCALIZATION; ENZYME POLYMORPHISM; ENZYME SYNTHESIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; LONG TERM CARE; MONOAMINERGIC SYSTEM; NEUROTRANSMITTER RELEASE; NONHUMAN; PROTEIN EXPRESSION; REVIEW;

ANIMALS; BRAIN; CYTOCHROME P-450 ENZYME SYSTEM; DOPAMINE; HUMANS; NEUROTRANSMITTER AGENTS; SEROTONIN;

EID: 84894134411     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/S1734-1140(13)71513-5     Document Type: Review

References (43)

1. Baum LO, Strobel HW: Regulation of expression of cytochrome P-450 2D mRNA in rat brain with steroid hormones. Brain Res, 1997, 765, 67-73. (Pubitemid 27374915)
2. Beck O, Jonsson G: In vivo formation of 5-methoxytryptamine from melatonin in rat. J Neurochem, 1981, 36, 2013-2018. (Pubitemid 11034773)
3. Berry MD: Mammalian central nervous system trace amines. Pharmacologic amphetamines, physiologic neuromodulators. J Neurochem, 2004, 90, 257-271. (Pubitemid 38938212)
4. Bertilsson L, Alm C, De Las Carreras C, Widen J, Edman G, Schalling D: Debrisoquine hydroxylation polymorphism and personality. Lancet, 1989, 1, 555. (Pubitemid 19075230)
5. Bromek E, Haduch A, Daniel WA: The ability of cytochrome P450 2D forms to synthesize dopamine in the brain: An in vitro study. Eur J Pharmacol, 2010, 626, 171-178.
6. Bromek E, Haduch A, Goembiowska K, Daniel WA: Cytochrome P450-mediates dopamine formation in the brain in vivo. J Neurochem, 2011, 118, 806-815.
7. Bromek E, Haduch A, Goembiowska K, Daniel WA: The formation of serotonin from 5-methoxytryptamine via cytochrome P450 in the brain in vivo -a microdialysis study. Eur Neuropsychopharmacol, 2013, 23, Suppl 2, S240-S241.
8. Chen AR, Irvine RJ, Bochner F, Somogyi AA: Morphine formation from codeine in rat brain: possible mechanism of codeine analgesia. Life Sci, 1990, 46, 1067-1074. (Pubitemid 20148780)
9. Cheng J, Zhen Y, Miksys S, Beyoglu D, Krausz KW, Tyndale RF, Yu A et al.: Potential role of CYP2D6 in the central nervous system. Xenobiotica, 2013, 43, 973-984.
10. Chow T, Imaoka S, Hiroi T, Funae Y: Developmental changes in the catalytic activity and expression of CYP2D isoforms in the rat liver. Drug Metab Dispos, 1999, 27, 188-192. (Pubitemid 29072070)
11. Daniel WA: The influence of long-term treatment with psychotropic drugs on cytochrome P450: the involvement of different mechanisms. Expert Opin Drug Metab Toxicol, 2005, 1, 203-217.
12. Daniel WA, Haduch A, Wójcikowski J: Inhibition and possibile induction of rat CYP2D after short-and longterm treatment with antidepressants. J Pharm Pharmacol, 2002, 54, 1545-1552. (Pubitemid 35331216)
13. Daniel WA, Haduch A, Wójcikowski J: Inhibition of rat liver CYP2D in vitro and after 1-day and long-term exposure to neuroleptics in vivo -possible involvement of different mechanisms. Eur Neuropsychopharmacol, 2005, 15, 103-110. (Pubitemid 39574405)
14. Di Chiara G, Imperato A: Drugs abused by humans preferentially increase synaptic dopamine concentrations in the mesolimbic system of freely moving rats. Proc Natl Acad Sci USA, 1988, 85, 5274-5278.
15. Ferrari R, Le Novère N, Picciotto MR, Changeux JP, Zoll M: Acute and long-term changes in the mesolimbic dopamine pathway after systemic or local single nicotine injections. Eur J Neurosci, 2001, 15, 1810-1818. (Pubitemid 35471906)
16. Funae Y, KishimotoW, Cho T, Niwa T, Hiroi T: CYP2D in the brain. DrugMetab Pharmacokin, 2003, 18, 337-349.
17. Gonzáles I, Peñas-Lledo, EM, Pérez B, Dorado P, Alvarez M, Llerena A: Relation between CYP2D6 phenotype and genotype and personality in healthy volunteers. Pharmacogenomics, 2008, 9, 833-840.
18. Haduch A, Bromek E, Daniel WA: The effect of psychotropic drugs on cytochrome P450 2D (CYP2D) in rat brain. Eur J Pharmacol, 2011, 651, 51-58.
19. Haduch A, Bromek E, Sadakierska-Chudy A, Wójcikowski J, Daniel WA: The catalytic competence of cytochrome P450 in the synthesis of serotonin from 5-methoxytryptamine in the brain: an in vitro study. Pharmacol Res, 2013, 67, 53-59.
20. Haduch A, Bromek E, Wójcikowski J, Goembiowska K, Daniel WA: Involvement of cytochrome P450 (CYP) in melatonin-serotonin transformation in the brain. The 11th World Congress of Biological Psychiatry, 23-27 June, Kyoto, Japan, 2013, P-18-013.
21. Hansson T, von Bahr C, Marklund M, Svensson JO, Ingelman-Sundberg M, Lundström J: Different regiospecificity in the hydroxylation of the antidepressant desmethylimipramine between rat brain and liver. Pharmacol Toxicol, 1992, 71, 416-419. (Pubitemid 23005943)
22. Hedlund E,Wyss A, Kainu T, BacklundM, Köhler C, Pelto-HuikkoM, Gustafsson JÅ,WarnerM: Cytochrome P4502D4 in the brain: Specific neuronal regulation by clozapine and toluene.Mol Pharmacol, 1996, 50, 342-350. (Pubitemid 26265139)
23. Hiroi T, Imaoka S, Funae Y: Dopamine formation from tyramine by CYP2D6. Biochem Biophys Res Commun, 1998, 249, 838-843. (Pubitemid 28441925)
24. Hiroi T, Kishimoto W, Chow T, Imaoka S, Igarashi T, Funae Y: Progesterone oxidation by cytochrome P450 2D isoforms in the brain. Endocrinology, 2001, 142, 3901-3908. (Pubitemid 32802662)
25. Kirchheiner J, Seeringer A, Godoy A, Ohmle B, Maier C, Beschoner P, Sim EJ, Viviani R: CYP2D6 in the brain: genotype effects on resting brain perfusion. Mol Psychiatr, 2011, 16, 333-341.
26. Kishimoto W, Hiroi T, Shiraishi M, Osada M, Imaoka S, Kominami S, Igarashi T, Funae Y: Cytochrome P450 2D catalyze steroid 21-hydroxylation in the brain. Endocrinology, 2004, 145, 699-705. (Pubitemid 38183813)
27. Mann A, Miksys S, Lee A, Mash DC, Tyndale RF: Induction of the drug metabolizing enzyme CYP2D in monkey brain by chronic nicotine treatment. Neuropharmacology, 2008, 55, 1147-1155.
28. Miksys S, Rao Y, Hoffmann E, Mash DC, Tyndale RF: Regional and cellular expression of CYP2D6 in human brain: higher levels in alcoholics. J Neurochem, 2002, 82, 1376-1387.
29. Miksys S, Rao Y, Sellers EM, Kwan M, Mendis D, Tyndale RF: Regional and cellular distribution of CYP2D subfamily members in rat brain. Xenobiotica, 2000, 30, 547-564. (Pubitemid 30449566)
30. Miksys S, Tyndale RF: Cytochrome P450-mediated drug metabolism in the brain. J Psychiatry Neurosci, 2013, 38, 152-163.
31. Patel S, Dulluc J, Geffard M: Comparison of serotonin and 5-methoxytryptamine immunoreactivity in rat raphe nuclei. Histochemistry, 1986, 85, 259-263.
32. Pinna G, Costa E, Guidotti A: Fluoxetine and norfluoxetine stereospecifically and selectively increase brain neurosteriod content at doses that are inactive on 5-HT reuptake. Psychopharmacology, 2006, 186, 362-372. (Pubitemid 43800838)
33. Schyman P, Usharani D, Wang Y, Shaik S: Brain chemistry: how does P450 catalyze the O-demethylation reaction of 5-methoxytryptamine to yield serotonin? J Phys Chem B, 2010, 114, 7078-7089.
34. Singh S, Singh K, Patel DK, Singh C, Nath C, Singh VK, Singh RK, Singh MP: The expression of CYP2D22, an ortholog of human CYP2D6, in mouse striatum and its modulation in 1-methyl 4-phenyl-1,2,3,6-tetrahydropyridine-induced Parkinson's disease phenotype and nicotine-mediated neuroprotection. Rejuvenation Res, 2009, 12, 185-197.
35. Srivastava G, Dixit A, Yadav S, Patel DK, Prakash O, Singh MP: Resveratrol potentiates cytochrome P450 2 d22-mediated neuroprotection in maneb-and paraquat-induced parkinsonism in the mouse. Free Radic Biol Med, 2012, 52, 1294-1306.
36. Strobel HW, Thompson CM, Antonovic L. Cytochromes P450 in brain: function and significance. Curr Drug Metab, 2001, 2, 199-214. (Pubitemid 32544554)
37. Ströhle A, Pasini A, Romeo E, Hermann B, Spalletta G, di Michele F, Holsboer F, Rupprecht R: Fluoxetine decreases concentrations of 3 α, 5 α-tetrahydrodeoxy corticosterone (THDOC) in major depression. J Psychiatr Res, 2000, 34, 183-186. (Pubitemid 30364917)
38. Thompson CM, Capdevila JH, Strobel HW: Recombinant cytochrome P450 2D18 metabolism of dopamine and arachidonic acid. J Pharmacol Exp Ther, 2000, 294, 1120-1130. (Pubitemid 30666868)
39. Uzunova V, Sheline Y, Davis JM, Rasmusson A, Uzunov DP, Costa E, Guidotti A: Increase in the cerebrospinal fluid content of neurosteroids in patients with unipolar major depression who are receiving fluoxetine or fluvoxamine. Proc Natl Acad Sci USA, 1998, 95, 3239-3244. (Pubitemid 28135886)
40. Voirol P, Jonzier-Perey M, Porchet F, Reymond MJ, Janzer RC, Bouras C, Strobel HW et al.: Cytochrome P-450 activities in human and rat brain microsomes. Brain Res, 2000, 855, 235-243. (Pubitemid 30085495)
41. Warner M, Gustafsson JÅ: Effect of ethanol on cytochrome P450 in the rat brain. Proc Natl Acad Sci USA, 1994, 91, 1019-1023. (Pubitemid 24048500)
42. Yu AM, Idle JR, Byrd LG, Krausz KW, Küpfer A, Gonzalez FJ: Regeneration of serotonin from 5-methoxytryptamine by polymorphic human CYP2D6. Pharmacogenetics, 2003, 13, 173-181. (Pubitemid 36324247)
43. Yue J, Miksys S, Hoffmann E, Tyndale RF: Chronic nicotine treatment induces rat CYP2D in the brain but not in the liver: an investigation of induction and time course. J Psychiatry Neurosci, 2008, 33, 54-63. (Pubitemid 351252497)